ABEONA THERAPEUTICS INC.
ABEO · XNASCIK 318306fmd_18E6WVJENCA20GAC02PTGGP5JX制造业 · 医药制剂模板: 标准
覆盖范围: 2010年1月01日 至 2026年9月30日，共 66 个期间
| 项目 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 营业总收入 | 1 | 1 | 3 | – | 10 | 3 | 1 | 4 | – | 6 |
| 租金收入 | 2 | – | – | – | – | – | – | – | – | – |
| 营业成本 | – | – | – | – | – | – | – | – | – | 2 |
| 毛利润 | – | – | – | – | – | – | – | – | – | 4 |
| 研发费用 | 11 | 17 | 39 | 49 | 30 | 39 | 29 | 31 | 34 | 27 |
| 销售、一般及管理费用 | – | – | – | – | – | – | – | – | 30 | 65 |
| 营业费用合计 | – | 29 | 61 | 77 | 91 | 93 | 52 | 51 | 64 | – |
| 营业利润 | (24) | (28) | (58) | (77) | (81) | (90) | (51) | (47) | (64) | (89) |
| 利息费用 | – | – | – | – | 4 | 4 | 1 | 0 | 4 | 4 |
| 其他营业外收入（支出） | 2 | 1 | – | – | – | – | 0 | 3 | 1 | 0 |
| 税前利润 | – | – | – | – | – | – | – | – | (64) | 71 |
| 所得税费用 | 0 | 0 | 0 | – | – | – | – | – | – | 0 |
| 持续经营净利润 | – | – | – | – | – | – | – | – | – | 71 |
| 净利润 | (22) | (27) | (57) | (76) | (84) | (85) | (40) | (54) | (64) | 71 |
| 归属于普通股股东的净利润 | (22) | – | – | – | – | (85) | (43) | (54) | (64) | 67 |